Reviewing OSR (NASDAQ:OSRH) and Dianthus Therapeutics (NASDAQ:DNTH)

OSR (NASDAQ:OSRH) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Institutional & Insider Ownership

55.3% of OSR shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares OSR and Dianthus Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81 million	5.38	-$27.06 million	($0.37)	-0.75
Dianthus Therapeutics	$2.04 million	2,977.37	-$162.34 million	($4.15)	-26.77

OSR has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for OSR and Dianthus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
Dianthus Therapeutics	1	0	12	1	2.93

Dianthus Therapeutics has a consensus target price of $124.27, indicating a potential upside of 11.86%. Given Dianthus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than OSR.

Profitability

This table compares OSR and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Risk & Volatility

OSR has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Summary

OSR beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.